MannKind Corporation to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C.
Rhea-AI Summary
MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET in New York. The company focuses on developing innovative therapeutic products for endocrine and orphan lung diseases. Interested parties can access the live webcast and replay for 14 days via the company’s website. MannKind aims to improve the lives of patients using their advanced inhalation devices and formulations for conditions like diabetes and pulmonary arterial hypertension.
Positive
- None.
Negative
- None.
Details
News Market Reaction – MNKD
The recorded move for MNKD in the trading session of this news was +9.04%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in a Fireside Chat at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:00 PM ET at the Lotte New York Palace Hotel.
Interested parties can access a link to the on demand webcast of the presentation from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations. The webcast replay may be accessed at the same location for 14 days.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.
Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.